Restek Seeks Approval to Import Rare Controlled Substances
Published Date: 3/4/2026
Notice
Summary
Restek Corporation wants to become an official importer of some controlled substances, including Amineptine and Mesocarb. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 3, 2026. This move could affect how these substances are brought into the U.S., but no direct costs are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Importer Registration to Import Listed Controlled Substances
On February 11, 2026, Restek Corporation applied to be registered as an importer of the listed basic classes of controlled substances (examples include Amineptine and Mesocarb, and many other Schedule I and II substances). The company says it plans to import these substances to manufacture exempted certified reference materials; interested parties may submit comments or request a hearing by April 3, 2026.
Import Authorization Excludes Finished Dosage Forms
The DEA states authorization for this registration will not extend to importing FDA-approved or non-approved finished dosage forms for commercial sale. Approval will be granted only when the registrant's business activity is consistent with 21 U.S.C. 952(a)(2).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06523 — Designation of P2P Methyl Glycidic Acid as a List I Chemical
Starting May 4, 2026, anyone handling P2P methyl glycidic acid—a key chemical used to make illegal drugs like methamphetamine—must follow new government rules and register with the DEA. This means all transactions, big or small, will be closely watched to stop illegal drug production. Businesses dealing with this chemical should act fast to stay legal and avoid penalties.
2026-06521 — Importer of Controlled Substances Application: Lipomed/LGC Standards
Lipomed/LGC Standards wants to become an official importer of certain controlled substances, like 3-Fluoro-N-methylcathinone. This means companies involved with these drugs can comment or ask for a hearing by May 4, 2026. If approved, it could impact how these substances enter the U.S., but no direct costs are mentioned yet.
2026-06051 — Importer of Controlled Substances Application: Usona Institute
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
2026-05912 — Bulk Manufacturer of Controlled Substances Application: SpecGx LLC
SpecGx LLC wants to become a big-time maker of some powerful and tightly controlled drugs, including things like psilocybin and fentanyl. People and companies already registered can share their thoughts or ask for a hearing by May 26, 2026. This move could shake up how these substances are made and handled, so keep an eye on the deadlines if you’re involved!
2026-05618 — Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.
2026-05486 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!
Previous / Next Documents
Previous: 2026-04298 — Extension of a Currently Approved Information Collection: Special Bond of Indemnity by Purchaser of United States Savings Bonds/Notes Involved in a Chain Letter Scheme
The Treasury is extending a form that helps people get refunds if they bought U.S. Savings Bonds through a tricky chain letter scheme. This affects individuals who need to fill out a special bond of indemnity form, which takes about 8 minutes to complete. Comments on this process are open until May 4, 2026, and there’s no new cost involved—just a smooth continuation of the current system.
Next: 2026-04300 — Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Corporate Whistleblower Awards Pilot Program Online Intake Portal
The Department of Justice is launching a new online portal for the Corporate Whistleblower Awards Pilot Program, making it easier for whistleblowers to submit tips. This change affects anyone who wants to report corporate wrongdoing and could speed up the process while protecting their info. The DOJ is asking for public feedback by May 4, 2026, to make sure the system works well and isn’t a hassle.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in